0000899243-21-024571.txt : 20210617 0000899243-21-024571.hdr.sgml : 20210617 20210617211346 ACCESSION NUMBER: 0000899243-21-024571 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210617 FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENSCHLER MARKUS MD CENTRAL INDEX KEY: 0001217598 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 211026882 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-06-17 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001217598 RENSCHLER MARKUS MD 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON MA 02421 1 1 0 0 See Remarks Common Stock 841954 D Stock Option (Right to Buy) 1.02 2028-12-10 Common Stock 106342 D Stock Option (Right to Buy) 1.19 2030-02-24 Common Stock 63408 D Stock Option (Right to Buy) 7.09 2031-02-21 Common Stock 500344 D Includes 125,226 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. The option vests at a rate of 18,337 shares per month at the end of each successive one-month period beginning January 3, 2019, for 40 months, and at a rate of 14,670 shares per month at the end of the 41st month, at which point the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. The option vested as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date . President and Chief Executive Officer Exhibit List: Exhibit 24 - Power of Attorney By: /s/ Andrew Gengos, Attorney-in-Fact 2021-06-17 EX-24 2 attachment1.htm EX-24 DOCUMENT

                           LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints Andrew Gengos and David
Gaiero, and each of them individually, with full power of substitution, as the
undersigned's true and lawful attorney-in-fact to:

        (1) prepare, execute in the undersigned's name and on the undersigned's
            behalf, and submit to the U.S. Securities and Exchange Commission
            (the "SEC") a Form ID, including amendments thereto, and any other
            documents necessary or appropriate to obtain codes and passwords
            enabling the undersigned to make electronic filings with the SEC of
            reports required by Section 16(a) of the Securities Exchange Act of
            1934, as amended, or any rule or regulation of the SEC;

        (2) execute for and on behalf of the undersigned, in the undersigned's
            capacity as officer and/or director of Cyteir Therapeutics, Inc.
            (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
            accordance with Section 16(a) of the Securities Exchange Act of
            1934, as amended, and the rules thereunder;

        (3) do and perform any and all acts for and on behalf of the undersigned
            that may be necessary or desirable to complete and execute any such
            Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any
            amendment or amendments thereto, and timely file such form with the
            SEC and any stock exchange or similar authority; and

        (4) take any other action of any type whatsoever in connection with the
            foregoing that, in the opinion of each such attorney-in-fact, may be
            of benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by each
            such attorney-in-fact on behalf of the undersigned pursuant to this
            Power of Attorney shall be in such form and shall contain such terms
            and conditions as each such attorney-in-fact may approve in each
            such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or each such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted.  The undersigned acknowledges that each
foregoing attorney-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 27th day of May, 2021.

                                        /s/ Markus Renschler
                                        -----------------------
                                        Name: Markus Renschler, M.D.